Eledon Pharmaceuticals, Inc. (ELDN) — 8-K Filings

8-K Filings (16)

• Eledon Pharmaceuticals Files 8-K on Financials — Nov 14, 2025 Risk: low
  Eledon Pharmaceuticals, Inc. filed an 8-K on November 14, 2025, reporting on its results of operations and financial condition. The filing also includes financi
• Eledon Pharmaceuticals Enters Material Definitive Agreement — Nov 13, 2025 Risk: medium
  Eledon Pharmaceuticals, Inc. entered into a Material Definitive Agreement on November 12, 2025. The company, formerly known as Novus Therapeutics, Inc. and Toka
• Eledon Pharmaceuticals Files 8-K on Financials — Nov 7, 2025 Risk: medium
  Eledon Pharmaceuticals, Inc. filed an 8-K on November 7, 2025, reporting on events as of November 6, 2025. The filing pertains to Results of Operations and Fina
• Eledon Pharmaceuticals Files 8-K — Aug 6, 2025 Risk: low
  Eledon Pharmaceuticals, Inc. filed an 8-K on August 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly k
• Eledon Pharmaceuticals Files 8-K with Corporate Updates — Jun 12, 2025 Risk: low
  Eledon Pharmaceuticals, Inc. filed an 8-K on June 10, 2025, reporting on several key events. These include amendments to its articles of incorporation or bylaws
• Eledon Pharmaceuticals Changes Auditors to BDO USA — Apr 7, 2025 Risk: low
  Eledon Pharmaceuticals, Inc. announced on April 1, 2025, a change in its certifying accountant. The company has appointed BDO USA, P.A. as its new independent r
• Eledon Pharma Appoints New CMO, Director — Dec 20, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on December 16, 2024, the appointment of Dr. Jonathan T. Hunt as Chief Medical Officer and the election of Dr. David M. E
• Eledon Pharmaceuticals Enters Material Definitive Agreement — Oct 30, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on October 29, 2024, that it entered into a material definitive agreement. The company, formerly known as Novus Therapeut
• Eledon Pharmaceuticals to be Acquired by Medicxi Affiliate — Oct 29, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on October 29, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Medicxi Ventures.
• Eledon Pharmaceuticals Reports Unregistered Equity Sale — Oct 1, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. reported on September 30, 2024, the unregistered sale of equity securities. The company, formerly known as Novus Therapeutics, Inc.
• Eledon Pharmaceuticals Enters Material Definitive Agreement — Sep 20, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on September 20, 2024, that it entered into a material definitive agreement. The filing does not disclose specific detail
• Eledon Pharma Restates Financials Due to Liability Accounting Error — Aug 14, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on August 13, 2024, that its previously issued financial statements for the fiscal year ended December 31, 2023, and the
• Eledon Pharma Changes Auditors Amidst R&D Expense Dispute — Jul 12, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on July 10, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged
• Eledon Pharma to be Acquired for $12.8M — Jul 10, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on July 10, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of the Pritzker family f
• Eledon Pharmaceuticals Files 8-K on Financials — May 13, 2024 Risk: low
  Eledon Pharmaceuticals, Inc. filed an 8-K on May 13, 2024, reporting on events from May 9, 2024. The filing pertains to Results of Operations and Financial Cond
• Eledon Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — May 7, 2024 Risk: medium
  Eledon Pharmaceuticals, Inc. announced on May 6, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of eq

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX